Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Antengene Corporation Limited
德琪醫藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6996)

VOLUNTARY ANNOUNCEMENT
INTENTION TO CONDUCT ON-MARKET SHARE REPURCHASE

This announcement is made by Antengene Corporation Limited (the "**Company**") on a voluntary basis to provide its shareholders and potential investors with information in relation to the latest developments of the Company.

The board of directors of the Company (the "**Board**") wishes to announce that it intends to exercise its powers under the general mandate (the "**Share Repurchase Mandate**") granted to the Board by the shareholders of the Company (the "**Shareholders**") at the annual general meeting of the Company held on June 10, 2026 (the "**AGM**"), to repurchase up to 67,924,413 shares of the Company (the "**Shares**"), representing 10% of the total number of the issued Shares (excluding any treasury shares) as at the date of the AGM.

On June 24, 2026, the Board resolved to utilize the Share Repurchase Mandate, that subject to market conditions, to repurchase Shares in the open market from time to time at a maximum aggregate consideration of HK$50 million (the "**Proposed Share Repurchase**"). The Board will determine whether the Shares repurchased will subsequently be cancelled or held by the Company as treasury shares, subject to market conditions and the capital management needs of the Group at the relevant time of the repurchases.

The Company will finance the Proposed Share Repurchase by its internal resources.

The Proposed Share Repurchase demonstrates the Company's confidence in its own business outlook and prospects and would, ultimately, benefit the Company and create value to the Shareholders. The Board believes that the current financial resources of the Company would enable it to implement the Proposed Share Repurchase while maintaining a solid financial position. The Board considers that the Proposed Share Repurchase is in the best interest of the Company and its Shareholders as a whole.

As of the date of this announcement, the Company has not repurchased any of its Shares.

Shareholders and potential investors should note that the implementation of the Proposed Share Repurchase by the Company will be subject to market conditions and at the Board's absolute discretion. There is no assurance of the timing, quantity or price of any repurchase, or whether the Company will make any repurchase at all. Shareholders and potential investors should therefore exercise caution when dealing in the Shares.

By the order of the Board
Antengene Corporation Limited
Dr. Jay Mei
Chairman

Hong Kong, June 25, 2026

As at the date of this announcement, the Board comprises Dr. Jay Mei and Mr. Donald Andrew Lung as executive Directors; and Ms. Jing Qian, Mr. Sheng Tang and Dr. Rafael Fonseca as independent non-executive Directors.